BioSpace News Archive

Penumbra, Inc., a global healthcare company focused on innovative therapies, reported financial results for the second quarter ended June 30, 2020.

DURECT Corporation announced financial results for the three months ended June 30, 2020 and provided a corporate update.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of the executive team will present during upcoming virtual investor conferences.

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced a change in the format of its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) from an in-person meeting to a virtual-only meeting format

Usona Institute has published a breakthrough technique in kilogram-scale synthesis of pharmaceutical grade psilocybin in the open-access journal ACS Omega.

Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, is very pleased that the Sean M Healey & AMG Center for ALS at Mass General announced the first patients have been enrolled into the HEALEY ALS Platform Trial being conducted at sites of the Northeast ALS (NEALS) consortium.

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that John Purpura, interim Chief Executive Officer, will be presenting virtually on Wednesday, August 12, 2020 at 9 a.m. ET in Track 5 at the Canaccord Genuity 40th Annual Growth Conference.

Chiasma, Inc., a commercial stage biopharmaceutical company, announced that it will host a conference call and live audio webcast on Monday, August 10, 2020 at 5:00 p.m. Eastern Time to discuss financial results for the quarter ended June 30, 2020 and to provide a business update.

Paratek Pharmaceuticals, Inc. announced that on July 31, 2020, the Company granted stock options and restricted stock units to three new employees of the Company.

Aduro Biotech, Inc., a clinical-stage biopharmaceutical company focused on developing therapies targeting the A Proliferation Inducing Ligand and Stimulator of Interferon Genes pathways for the treatment of cancer, autoimmune and inflammatory diseases, provided a business update and reported financial results for the second quarter ended June 30, 2020.